Distinct from our work, Mucciolo and colleagues reported that in pancreatic cancer, stromal EGFR activated by AREG is involved in the acquisition of pro-tumorigenic properties that favor cancer cells via myofibroblast activation.4 This evidence concerns the gene AREG and pancreatic neoplasm.